Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Liabilities: 2021-2025

Historic Total Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $176.9 million.

  • Kiniksa Pharmaceuticals International's Total Liabilities rose 49.59% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year increase of 49.59%. This contributed to the annual value of $142.1 million for FY2024, which is 62.45% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Total Liabilities of $176.9 million as of Q3 2025, which was up 6.50% from $166.1 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Total Liabilities high stood at $176.9 million for Q3 2025, and its period low was $38.8 million during Q3 2021.
  • Its 3-year average for Total Liabilities is $111.9 million, with a median of $107.3 million in 2024.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Total Liabilities skyrocketed by 95.68% in 2022 and then declined by 18.47% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Total Liabilities (Quarterly) stood at $47.8 million in 2021, then soared by 33.00% to $63.5 million in 2022, then soared by 37.72% to $87.5 million in 2023, then spiked by 62.45% to $142.1 million in 2024, then skyrocketed by 49.59% to $176.9 million in 2025.
  • Its Total Liabilities stands at $176.9 million for Q3 2025, versus $166.1 million for Q2 2025 and $141.8 million for Q1 2025.